Portfolio companies
|
CytoGuide focuses on the development of novel two-component drugs that has the potential to maximise the effectiveness of a well-known Rheumatoid Arthritis treatment while drastically minimising its side effects. Novo A/S board representative: Henrijette Richter |
|||
|
|
|||
|
|
|||
|
EpiTherapeutics is a drug discovery and development company formed in 2008 based on discoveries at the Biotech Research and Innovation Centre (BRIC) at Copenhagen University. The company develops new drugs with the ability to regulate epigenetic mechanisms. The company’s lead program targets prostate cancer. Novo A/S board representative: Stephan Christgau |
|||
|
|
|||
|
|
|||
|
Inagen was formed in 2007 to develop new therapies for viral diseases. The company’s primary candidate is treatment for Cytomegalovirus (CMV). There is a great unmet need for effective and affordable treatment to eradicate this serious disease. Novo A/S board representative: Stephan Christgau |
|||
|
|
|||
|
|
|||
|
MycoTeQ discovers and develops novel natural antibiotics against gram-negative bacteria. The pipeline of the company is based on natural small molecules produced by microfungi. A proprietary compound library representing microfungi from a range of biological niches forms the core of the discovery process. Novo A/S board representative: Henrijette Richter |
|||
|
|
|||